Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of [S,S]-reboxetine in chronic painful diabetic peripheral neuropathy
2006-001307-11Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of reboxetine in diabetic polyneuropathy (DPN) (2 arms), sponsored by Pfizer. Primary endpoint: Long-term safety and tolerability of [S,S]-reboxetine. Started Jun 2006; status: terminated.
02
Drugs
reboxetine
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2006-001307-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001307-11.